by andrewmm2007 | Jan 18, 2023 | Press Releases, Featured Press 2
SAN FRANCISCO, January 18, 2023 – Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat cancers,...
by andrewmm2007 | Nov 1, 2022 | Press Releases, Featured Press
– Multi-center Phase 1/2 study to evaluate safety and efficacy of TT-816, an oral CB2 receptor antagonist acting as an immune checkpoint inhibitor while promoting T cell infiltration of cold tumors and stimulating NK cell tumor killing – –...
by andrewmm2007 | Jun 1, 2022 | Featured Press 2, Press Releases
First-in-class, oral cannabinoid CB2 antagonist acting as an immune checkpointinhibitor has potential to enhance immune response to treat solid tumors Company on track to initiate Phase 1/2 clinical trial in third quarter 2022 SAN FRANCISCO, June 1, 2022 – Teon...
by andrewmm2007 | Mar 8, 2022 | Featured Press, Press Releases
Recognized as a visionary industry leader with exceptional experience in buildingorganizations from product development to commercialization, and a strong focus on people, families, and communities affected by cancer Joining team of highly prominent immuno-oncology...
by andrewmm2007 | Apr 5, 2021 | Press Releases
SAN FRANCISCO, April 5, 2021 – Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit immunosuppressive and cancer-promoting signaling pathways, today announced the forthcoming oral presentation of preclinical data on selective...
by andrewmm2007 | Feb 22, 2021 | Press Releases
SAN FRANCISCO, CA, February 22, 2021 – Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways, today announced the completion of a $30M Series A financing. Thefinancing was...
